Member Info for sadoldgit

Warthog, are you referring to the statement by TM of a 'transformational deal' at the end of 2012 that never materialised. SP dropped by over 50% but did recover a tad.

Remixed

Good morning PC1954,

Unite was very much a ramper a while back.

That from mid 2021

'Come buy SAR my lord

Come buy SAR

Oh lord come buy SAR

For about 15 billion quid'

if it bought in at 2017 the price circa 0.7 p per share then equal 35 p per share now/

2021 SP peaked at over 9p per share so a considerable 12 fold increase.

Mentions the 15 billion, god knows where that came from.

with current shares in circulation that makes about £120 a share.

A touch of greed comes to mind, someone in their mid 30's and a tad immature. Market sentiment has had a negative impact on the SP but has done nothing to weaken SDC compounds themselves.

It has slated the board ever since, is sees a poor SP but has no idea of the potential worth of our compounds. It cannot comprehend the market, changes in approval procedures, and the prospect of new classes of inhibitors posing a threat.

A touch of greed comes to mind, someone in their mid 30's I feel, and a tad immature. Market sentiment has had a negative impact on the SP but has done nothing to weaken SDC compounds themselves.

Manipulation is definately involved here. 18,000 pounds worth of shares the SP drops approx 6%. it is being played and we are not the only one on AIM.

Regards

Good morning youngJev.

I recommend watching/ listening to it all but the part that stands out to me above all else is when John reader gets asked a question, listen from 43:25. When being asked if there was any issue with tox results he said "Well there was no toxicity concerns raised from the results from phase 1 trail, So I think the decision to look at extended tox studies was purely base on regulatory requirements to conduct phase 2 studies." where it gets interesting. "And we've had a steer I suppose from a potential commercialisation partners (PLURAL). They didn't see the benefit of short validating phase 1b studies because the targets a clinically validated"

It sums up what I havestated several times before in that the toxicology studies are required to establish the effects of long term use and suitability, efficacy in psoriasis is proven but the biggest effect is long possibly life long usage and that has one hell of an impact on the commercialisation value.

With the authorisation of an allosteric TYK inhibitor approved for clinival use the safety profile acceptance criteria is raised. You are in effect guilty until can prove otherwise.

I am sure big pharma have known about this over the years especially as Sotyktu not approved late2022 early 2023.

Good response Youngjev.

I will respond to the last part of your post a little later. It is an interesting point.

Carter19 i dont think it could do a 2 piece jigsaw even if it had a picture on the box.

Couldn't tell the difference between a 5000 piece jigsaw and a packet of cornflakes with a dirty great big red chicken painted on the side.

KoolKat15, steady on.

My original purchases were around 0.2 to o.6p old money.

i sold circa 1 million at 9.2 p

I have sold more in 2021 but have bought back in at lower price cetainly not at a spike as you state without factual info.

It is you I believe that have bought at a spike and sold at a loss. I am sure you posted indications of this recently.

You are way out of your depth as indicated by your posts. that proof enough.

You post

'"I'm so confident that we're in deep into negotiation and not with 1 pharma but with a couple.

I didn't hear him say "partner" I heard "partners" which is excellent for sareum considering the squeeze on cash.

Best in class? Nothing yet says we won't be".

YoungJev

'It is pretty poor to make these claims and when people ask for proof you and no one else on this board have anything on hand to back up your claims.'

Where have I made those above statements. Show me where they are by copying and pasting so that I have the opportunity to reply.

If you cannot prove by copying and posting that you intimate as my statements then all this does is reinforce the fact that you are indeed way out of your depth.

i did put down that we should not experience any problems with safety and efficacy a couple of years back with 1801 compound. I notice you dont mention this.

Like any loser that has lost you try character assassination to undermine.

Youngjev posts

'Best in class? Nothing says it wont be'

Perhaps you could provide factual information that contradicts this statement.

I take it that you are knowledgeable with regards to Jak inhibitors both old and in current development, along with their selectivity and reasons for withdrawal from some indications that are becoming dominated by Tyk2 Inhibitors.

KoolKat15, word of advice dont try and be something that you are not ie clever.

It is you that have bought at a spike.

There are HNWI's that have bought at a spike and indeed created a spike, I take it you bought on one of these spikes.

Up

KoolKat,

'IMHO, apart from a potential spike, as with all small cap, I honestly don't think any of Sareum's products will turn into revenue. If the science was proven and the drugs were so innovated why has no large pharmaceutical taken them out? In addition, why did the MHRA refuse Sareum a clinical trial? This is a fact btw!'

The MHRA did not refuse sareum a clinical trial only that they were unable which is not the same.

There is also a fact,that is indeed a fact in that sareum had contacted MHRA to inquire as to the reasons for the inability to grant authorisation for clinical trial.

To date there has been no response. Tims words to me ' they are not going to respond as they would have to admit that they (the MHRA) are in the wrong and they will not admit that.'

All the preclinical work carried out to GLP and MHRA requirements Tim tells me, he is getting a tad wound up at this stage and topic was dropped.

Of course Koolkat you have your negative opinion which you post and Tim Mitchell with a PhD who is far more closer to the top of the knowledge tree than you eill ever be, so i know who i will take notice of account from.

Sorry but you are way way out of your depth koolKat, not your fault I know.

Really, why on earth do you bother to post here?

Regards

That about my only gripe at the moment 1801 compound preparation. But not a bad thing in great scheme of things as no problems with storage decline.

News looking up a tad on the investment front.

MegRS300,

very amusing, it takes many years to put a pharmaceutical compound into commercialisation. 10 to 15 years on average as you know yourself. A good analogy by you of the happy clappy meal.

I am sure some think all you have to do is get on your mob, phone some phuker up even by using an electronically devised random number, and of course make a deal.

It dont matter that they are watching Corrie or I'm a Celebrity, not in your part of the world, dont speak your language, or maybe sitting on the Egdar Alan creating a number 2 after the happy clappy meal.

Sdc compounds been ongoing now around 12 to 13 years in their development, only a few months and we will know just how good 1801 is. Not a case of failure here as mentioned by some that dont understand unless of course you take lower value as failure.

investment should improve

https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025?v=preview

Interesting post Damion with regards to TLL Pharmaceuticals’ TYK2/JAK1 inhibitor.

Whilst talking with Tim post AGM the topic of 1801 1802 difference was bought up.

1801 as autoimmune they did not want jak 1 crossing the blood brain barrier, acceptable for immuno oncology but not auto immune. Albeit he would not delve in deeper.

What i do find a tad annoying is that when deciding to undertake these adittional toxicology studies, why the Bod did not decide to have 1801 compound made in good time in preparation for study start.

All projects have a critical path.

In this instance it is the 4 month trial period. Not made into 6 months put the delay of 2 months prep work.

However, it is now mentioned mid year which has given the project a little bit of slippage already. Completion in H1 end of June, mid year June to end of July or thereabouts,

Regards

Good report Damion with the associated link.

Lage Pharma are not the good guys that they like people to think,

BMS provide funding to departments that the FDA consult with regards to approval for use and the advice on restrictive measures.

Regards

Good morning.

'With the science already proven with other companies tyk2 products' ?

With regards to Jak inhibitors 1,2 &3 they are classed as inhibitors with boxed warnings given to all Jak inhibitors as they exhibit off target effects form moderte to major adverse cardio events.

Allosteric TYk2 has proven no such risks are involved and it is accepted that TYK2 is first class safety profile.

However, by being overly selective it can limit its efficacy.

An inhibitor with TYK2 in does not make it safe.

Early jak inhibitors, I will use this term for Jaks 1,2 and 3 have insufficient selectivity to satisfy recent safety critera for clinical use as first in line treatment.

Hence they are repurposing in areas of so called high unmet need.

Breprocitinib, Ropscacitinib, TYK2 Jak1, Tyk2 Jak2 respectively are inhibitors of which Pfizer indicated that they had found a promising inhibitor/inhibitors for Psoriasis ( other indications of course)

There has always been associated off target events compromising safety with JAK inhibitors.

Pfizer now have 2 promising candidates for treatment in autoimmune.

Then come along at end of 2022 and we have Deucravacitinib (Sotyktu) an allosteric inhibitor working via the allosteric or JH2 domain which is claimed to regulate the active site JH1 domain. No safety concerns.

So you can see the interest and high price paid by BMS for ( nimbus of 74 billion from memory) for the company which then sold the vast majority of the remaining pipeline off.

Deucravacitinib has in effect destroyed any Jak inhibitor with regards to commercialisation potential irrespective of selectivity.

Both Priovants candidates recently ceased development indications. (Safety concerns)

Is there a good side to this?

Well yes, we have selectivity and for compounds to be effective we require adequate selectivity but not over selectivity.

With SDC1801 we have at least a 20 fold selectivity of TYK2 over Jak 1,2 and 3.

Jak2 can cause problems by pairing with itself. This is of significant concern. However, from the Phase 1a results there was no Jak2 activity detected. That is impressive.

Are we the first TYK2 Jak inhibitor that does not compromise safety over efficacy with Jak2 activity?

Jak1 can cause problems if it is overly selective over other Jakis and indeed TYK2.

In effect by the addition of an optimum amount of Jak1 ( which will include Jaks 2 and 3 the amounts dependant on molecular structure) can therefore enhance the efficacy of wholly selective Tyk2 whilst maintaining the industry associated safety profile associated with allosteric TYK2.

Potential commercialisation value is huge.

But of course clinical trial safety data and recently additional requirements for toxicology studies will be needed to satisfy a partner of any sort before formal discussions.

NOTE THE HNWI RAISING OF FUNDS POST PHASE 1a CLINICAL TRIAIL.

Regards

Joey, good morning.

if you dont like just filter.

Or those that prefer I dont post then I can always do that.

Put it to a vote haha

Good afternoon Potters. I had mentioned on two if not 2 occassions when I sold in 2021. So dont give me this .none of you you guys came forward' bs as that all it is apart from somethething else you have fabricated

You dont bother reading my posts as stated many times by yourself.

That is laughable as you must at times or not made your usual reply full of flaws.

300 to 500 a week investment a reasonable amount of commitment.

We can see you see the massive potential and is valued greater than you than by me. Yet you say I am bullish or rampers who ony see one side.

There is a diffrence here Potters between you and I.

I am an investor and hence will see it through to the end ie on licence or buyout. I do not see failure here as an outcome.

I still add too.

With regards to new investors I would advise that they do their homework before buying.

You state risks that you point out.

What are these risks?

Or are these risks hurdles?

Nothing is guaranteed for sure.

Results will allow Phase2 studies that 99.99% certain.

But of course peoples getting impatient waiting for confirmation of start. is this a risk or a hurdle? its a hurdle!

Raising of further funding, risk or hurdle. To a point it is a risk as in not a risk of comapany failure but likely to lead to share devaluation, it is a hurdle too.

Sareums Aim to on licence at late preclinical or early/mid stage clinical.

they could do both at same time.

hat is your opinion of this 1 in 10 chance of success from phase1 to commercialisation. A statistic nothing else.

Breprocitinib withdrawn from 6 phase 2 indications has FDA approval in one indication and undergoing 2 futher trials in other indications.

As you may or may not know 2 out of 3 drugs fail at phase 2 as this is where toxicity/ adverse events v efficacy rear their ugly head.

So with Breprocitinib they have had 9 bites at the cherry. No mention of this by the naysayers like yourself.

completely changes the 90% failure risk.

Deucravacitinib good safety failed in UC but gave reasonably better than placebo results in Psoriasis.

It may well reach approval for at least 3 indications with SLE being one of them.

How do you then apply the statistical 1 in 10 chance of success to the above compounds?

Or is it not subject to chance. If it is not subbject to chance then there must be a reson for the bias.

The most likely reason is jak selectivity and molecular structure. It is not just as simple as sayin jak1 Jak2 jak3 and TYk2.

Early inhibitors had higher failure rate.

Rather like the good old silicon chip

I were a machine tool fitter around 1982 and made silicon wafering machines. At that time chip failure rate was close to 80% within around 10 years 90% pass rate

Trust you enjoy reading

hugs and kisses

Good evening PC1954.

Not sure if you were aware of the following, taken from 19th Dec 2024.

'The recently announced additional funding of £3.4 million through share subscriptions and in addition the receipt of a A$1.9 million (c. £1 million) Australian tax credit, will support the next steps in the programme. This includes preparing the asset for Phase 2 clinical trials by undertaking additional drug product synthesis and toxicology studies. These studies, expected to conclude by mid-2025, are designed to meet regulatory requirements for longer dosing periods.'

I do recall from the AGM a comment from John R about maybe having to manufacture more of the compound.

In a way a good thing as you have previously remarked on yourself.

Potnak.

Your last 4 words were right.

'The buck stops with them though. Not market manipulation. It's now two months since p1a data was signed off. Is that enough time to spin up a tox study. I don't know. Genuinely, I don't know.'

As for market maniulation that does happen with whales, I take it you know what they are and how they work. absolutely rife in the AIM market now.

Potnak and an even smaller narrow minded bunch like yourself that instigate the arguments.

Its ok though Potters Reality10 loves you.

xxx

Afternoon potnak,

most people not give a to55 what you say. you are starting to sound like a little scolded child.

I should not think the likes of Sareum give a monkeys about your investment Potnak. You are a shareholder when it suits you. Were you a share holder when you sold up? At the moment in time it would not matter to you if the company went tits up.

Did you take part in the equity raise? No you did not.

Exactly what have you done for the company apart from opinionate outcomes of billions to complete failure and anything in between.

You dont understand the science and try undermine wherever possible.

You bought me up in the subject.

I will happily continue.

Mummy those boys are being condescending to me again ooohhhhaaaaahhhhh.

Spot on with that one PC1954

Nothing to add to that.

Regards

I will post it again laz.

poinless to explain to them as they are unable to understand. Surfie a born loser just look at his post history on other shares.

'SOG has explained most of this stuff a million times but for fun I put sareums news from July into chatGBT, I recommend anyone to do it as it breaks things down so nicely. Put a smile on my face anyway haha.

Mentions things such as “The biggest challenge for TYK2/JAK1 inhibitors is that high doses often lead to toxicity issues (like blood cell suppression & kidney damage).

Sareum has now proven that SDC-1801 can reach high therapeutic levels without these serious side effects.

This means better efficacy at safer doses, giving SDC-1801 a potential edge over Pfizer’s brepocitinib (which has dose-limiting side effects).”

Also “Strong Competitive Position vs. Pfizer & Bristol-Myers Squibb

Sotyktu (BMS's TYK2 inhibitor) has a shorter half-life (~10 hours), meaning SDC-1801 could offer longer-lasting effects with fewer doses.

Brepocitinib (Pfizer's TYK2/JAK1) struggles with dose-limiting side effects—but SDC-1801 appears to avoid these issues, making it a safer alternative.

If Phase 2 confirms these advantages, big pharma will be very interested in licensing or acquiring SDC-1801.” Last but not least “Major Buyout or Licensing Potential

Sareum has just de-risked one of the biggest hurdles in clinical drug development: safety at high blood levels.

If Phase 2 confirms strong efficacy, Sareum’s valuation could skyrocket, as big pharma prefers to acquire de-risked, late-stage assets.

Potential Buyout Target: Pfizer, GSK, or AbbVie may now be watching SDC-1801 very closely. Full Phase 1 Data Unblinding – Once the data is officially unblinded & published, we’ll get an even clearer picture of safety & efficacy signals.

Phase 2 Trial Design & Regulatory Clearance – If Phase 1 data is strong, Sareum will secure approval to begin Phase 2, likely in late 2025.

Potential Pharma Interest & M&A Speculation – If the market recognizes this safety profile as superior, Sareum’s share price could begin to re-rate before Phase 2 even starts.“

Nothing new here but the potential will never not be exciting. A lot of you will remember when the price went to 9p but I hope you also remember when you thought “should’ve bought more at 0.5p”. The board have definitely not been the best when making business decisions however once they pull this all off (which I think they will) I hope you apologise and thank them for their genius autistic brains!!'

Regards

A great post from you YoungJev.

Sums up nicely on the potential of 1801,

Selectivity is all important but not the limiting factor. Certain molecular formulations also pose a risk creating associated adverse events of which are SDC compounds do not have the same structural base.

It is a complex issue.

If l manage to find time l will post about this in greater detail.

Is it any wonder why so much patent protection has been put around our SDC compounds with around 30 patented molecules.

No not a patent for each one individually but protected as a group.

Your post in effect knocks the wind out of the sails of certain posters here that's how we say a tad on the negative side.

I have been here now 13 years.

At one time over 700k up.

Some here hold much more than l do and have been here longer.

Very little point l feel in my posting anything more . Too many likes for the nay sayers and doom mongers.

Regards and have a good day

Wes

Ratatat, l very much doubt anyone would report such an unbiased and completely inoffensive post.

Regards

Blockbuster.

My perogative to post as and when l so choose.

I take it you have read my posts but doubt you can comprend the importance of.

From your posting l believe you have not been invested here long and hence have very little idea of either Sareum or its compounds.

To me tge current SP is mo problem as such as will transfer 20k's worth of shares to ISA or buy 20k to put in new allowance year.

Of course in effect my plans are none of your concern.

Reality10 is in the same mould as Puma / Robin Hood of AIM.

Surely you remember the pushing of sell up now and buy back later.

Puma plan. He stated that he would or to be more precise MAJWANDCO short and the buy back at rock bottom then make as he termed whoosh loads of money.

FWIIW my opinion is it bought in after April 24.

Valuations he made of 50 to 70p in September.

Of course did not come to fruition.

Now we have the similar Puma type posting everyone sell. SOG is paid ramper ( no l am not l have been here nigh 13 years and have at times posted on the negatives)

It just irritates me that when the share price slides we are inundated by traders that complain.

Now with regards to ramping Reality 10 has stated that he intends to buy back after the summer as he believes there will be a takeover after toxicology results.

Is this not ramping?

I will end this note on, as usual you have nothing of any worthwhile input for the benefit of the company or the long term shareholders here.

Be careful what you state, as you are by posting statements that are not only false but also libellous.

Regards